Drug intelligence / Profile preview

131I-acitretide

Development stage: Unknown
Lead developer: Yangtze River Pharmaceutical Group
Modality: Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

131I-acitretide is an investigational radiopharmaceutical designed for the treatment of advanced malignant solid tumors. It consists of a monoclonal antibody labeled with Iodine-131, which is engineered to target Carcinoembryonic Antigen (CEA). The drug is being developed by a collaboration including the Ministry of Science and Technology, China, 307th Hospital of Chinese People's Liberation Army, and Shanghai Haikang Pharmaceutical Technology & Development Co. Ltd.

Other names: 碘131爱克妥昔单抗注射液

Beyond the preview

Go deeper on 131I-acitretide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 131I-acitretide.

Explore the full profile